Managing hyperglycaemia in people with DM and CKD: establishing chronic co-pathology

Published on August 11, 2020   28 min

Other Talks in the Category: Diseases, Disorders & Treatments

0:00
Hello. My name is Peter Winocour. I'm a diabetes consultant in the United Kingdom. I'm the Clinical Director for the East and North Herts Institute of Diabetes and Endocrinology and I was a founder of the Association of British Clinical Diabetologists and Renal Association- a diabetes kidney clinical specialty group.
0:20
These are my declarations of interest for the presentation I'm delivering this morning.
0:28
I'm going to talk, today, really, about the interlink between diabetes and chronic kidney disease. This is a fairly recent data set from the United States, looking at both the incidence and prevalence of end-stage kidney disease in general. You can see here that, really, there was a slow increase in the incidence of end-stage kidney disease, probably till the year 2000, which has been to a greater or lesser extent, maintained for the last few years. But, as the population is surviving longer with this significant morbidity, you can see that there's been a progressive increase in the prevalence of end-stage kidney disease in the United States, and this is paralleled by data from other countries, including the United Kingdom.
1:12
When it comes to diabetes and end-stage kidney disease, this slide shows quite clearly that there is a cumulative impact of diabetes, and in addition to that, of kidney disease, in terms of lifespan. You can see that, particularly for women, the presence of diabetes and kidney disease, as we'll define shortly, can shorten the lifespan by over 16 years in women, if this kidney disease develops early in diabetes. It's around about 15 years in men.
Hide

Managing hyperglycaemia in people with DM and CKD: establishing chronic co-pathology

Embed in course/own notes